BioMAP® Diversity PLUS Panel
약물에 의한 12가지 Human primary cell-based system의 biomarker readout 변화를 BioMAP reference database와 비교하여 약물의 효능을 예측할 수 있는 서비스
| Eurofins DiscoverX(Eurofins Discovery) 공식 대리점
INTRODUCTION
BioMAP Diversity PLUS Panel은 인간의 다양한 조직과 질병을 체외에서 구축한 human primary cell-based model과 DiscoverX사가 보유한 4500개 이상의 reference database를 통해 약물 개발 프로세스의 초기 단계에서 후보 약물의 효과와 안정성에 대해서 임상 수준으로 확인할 수 있는 phenotypic profiling 서비스입니다.
Inflammation, Auto-immunity 등 면역관련 질환 연구자 및 치료제 개발자, 암 치료제 개발자 분들에게 추천 드립니다.
FEATURES
12 individual BioMAP human primary cell-based co-culture systems
In vitro에서 다양한 조직과 질병 모델을 재현함으로써 약물의 효능 예측
148 clinically relevant biomarker readouts
임상 결과를 바탕으로 축적된 biomarker를 정량적으로 측정하여, 그 결과를 바탕으로 약물의 작용 기전을 규명
>4,500 reference compounds from BioMAP database
임상적으로 검증된 다양한 종류의 약물에 대한 database 보유
ADVANTAGES
In vivo testing, clinical trial 전에 약물의 효능 및 독성을 미리 예측함으로써 약물의 안정성을 향상시킬 수 있습니다.
임상적으로 검증된 다양한 약물에 대한 reference database 와의 비교 분석을 통해 후보 약물의 효능을 효과적으로 예측할 수 있습니다.
질병 관련 biomarker를 통해 약물의 작용 메커니즘을 규명하여 새로운 약효를 찾음으로써 다른 질환으로 용법을 확대할 수 있습니다. (Drug repurposing or repositioning)
Final report 항목
| Deliverables | Description |
| Profile analysis | Test agent에 의한 biomarker의 변화를 통해 mechanism of action (MoA)를 분석할 수 있습니다. |
| Benchmark analysis | Test agent의 4가지 농도 중 한가지 농도와 benchmark compound 한가지 농도에 대한 biomarker의 변화를 비교 분석합니다. |
| Similarity search analysis | BioMAP reference database에 존재하는 4,500개 이상의 agent 중 test agent에 의한 biomarker의 변화 패턴과 가장 유사한 패턴을 보이는 agent를 보여줌으로써 test agent의 생물학적 기능을 예측할 수 있습니다. |
| Cluster analysis | Test agent를 3개 이상 분석 의뢰하였을 때, agent 간의 생물학적 기능 유사성이 존재하는지 pairwise correlation analysis를 통해 확인할 수 있습니다. |
| Mechanism HeatMAP Analysis | 이미 알려진 약물의 대표적인 19가지 mechanism 내의 biomarker의 발현 패턴과 test agent에 의한 발현 패턴을 heatmap format으로 비교함으로써 test agent의 주요 mechanism을 예측할 수 있습니다. |
서비스 개요 및 샘플 준비 방법
| 서비스 유형 | Diversity PLUS |
| Biomarker Readout | 148 |
| 실험농도 (Top Concentration) |
선택 가능 |
| 농도 개수 | 4개 농도(1/3 또는 1/10) |
| Biomarker Readout | Singlicate |
| Sample Volume* (Small Molecule) | 150ul |
| Sample Volume* (Biologics) | 1.5ml |
| 서비스 장소 | St Charles,MO USA |
*실험할 농도의 1000x DMSO/PBS/D.W. stock으로 준비
세미나 영상
REFERENCE LIST
| No. | Year | Title | PMID |
| 1 | 2021 | Use of a rapid human primary cell-based disease screening model to compare next generation products to combustible cigarettes. Simms L, Mason E, Berg EL, Yu F, Rudd K, Czekala L, Trelles Sticken E, Brinster O, Wieczorek R, Stevenson M, Walele T. Current Research in Toxicology. 2021;2:309-321. |
34485931 |
| 2 | 2021 | Expanding the drug discovery space with predicted metabolite–target interactions. Nuzzo A, Saha S, Berg E, Jayawickreme C, Tocker J, Brown JR. Commun Biol. 2021;4:288. |
33674782 |
| 3 | 2021 | Investigating Molecular Mechanisms of Immunotoxicity and the Utility of ToxCast for Immunotoxicity Screening of Chemicals Added to Food. Naidenko OV, Andrews DQ, Temkin AM, Stoiber T, Uche UI, Evans S, Perrone-Gray S. Int J Environ Res Public Health. 2021;18(7):3332. |
33804855 |
| 4 | 2021 | The future of phenotypic drug discovery. Berg EL. Cell Chemical Biology. 2021;28(3):424-430. |
33529582 |
| 5 | 2020 | ILB® resolves inflammatory scarring and promotes functional tissue repair. Hill LJ, Botfield HF, Begum G, Qureshi O, Vigneswara V, Masood I, Barnes NM, Bruce L, Logan A. NPJ Regen Med. 2021;6:3. |
33414477 |
| 6 | 2020 | Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans. Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, Coquery CM, Neil J, Pryor WM, Mayhew D, Rajpal DK, Creech K, Furst S, Lee J, Wu D, Rastinejad F, Willson TM, Viviani F, Morris DC, Moore JT, Cote-Sierra J. J Invest Dermatol. 2017;137(10):2110-2119. |
28595996 |
| 7 | 2020 | The activities of drug inactive ingredients on biological targets. Pottel J, Armstrong D, Zou L, Fekete A, Huang X-P, Torosyan H, Bednarczyk D, Whitebread S, Bhhatarai B, Liang G, Jin H, Ghaemi SN, Slocum S, Lukacs KV, Irwin JJ, Berg EL, Giacomini KM, Roth BL, Shoichet BK, Urban L. Science. 2020;369(6502):403-413. |
32703874 |
| 9 | 2019 | Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Berg EL. Front Big Data. 2019;2. doi:10.3389/fdata.2019.00047. |
33693370 |
| 10 | 2019 | Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. Singer JW, Al-Fayoumi S, Taylor J, Velichko S, O’Mahony A. PLOS ONE. 2019;14(9):e0222944. https://doi.org/10.1371/journal.pone.0222944 |
31560729 |
| 11 | 2019 | Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models. Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, O’Mahony A, Zimmerli SC, Bruns L, Bender AT, Schroeder P, Grenningloh R. The Journal of Immunology. 2019;202(10):2888-2906. https://doi.org/10.4049/jimmunol.1800583 . |
30988116 |
| 12 | 2019 | Assessing bioactivity-exposure profiles of fruit and vegetable extracts in the BioMAP profiling system. Wetmore BA, Clewell RA, Cholewa B, Parks B, Pendse SN, Black MB, Mansouri K, Haider S, Berg EL, Judson RS, Houck KA, Martin M, Clewell HJ, Andersen ME, Thomas RS, McMullen PD. Toxicology in Vitro. 2019;54:41-57. https://doi.org/10.1016/j.tiv.2018.09.006 . |
30218698 |
| 14 | 2018 | Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells. Orellana A, García-González V, López R, Pascual-Guiral S, Lozoya E, Díaz J, Casals D, Barrena A, Paris S, Andrés M, Segarra V, Vilella D, Malhotra R, Eastwood P, Planagumà A, Miralpeix M, Nueda A. PLOS ONE. 2018;13(1):e0189247. |
29320511 |
| 15 | 2018 | Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing. Rubin J, Mansoori S, Blom K, Berglund M, Lenhammar L, Andersson C, Loskog A, Fryknas M, Nygren P, Larsson R. Oncotarget. 2018;9(56). https://doi.org/10.18632/oncotarget.25713 . |
30112108 |
| 16 | 2018 | Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells. Orellana A, Garcia-Gonzalez V, Lopez R, Pascual-Guiral S, Lozoya E, Diaz J, Casals D, Barrena A, Paris S, Andres M, Segarra V, Vilella D, Malhotra R, Eastwood P, Planaguma A, Miralpeix M, Nueda A. PLOS ONE. 2018;13(1):e0189247. https://doi.org/10.1371/journal.pone.0189247 |
29320511 |
| 17 | 2018 | Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. O’Mahony A, John MR, Cho H, Hashizume M, Choy EH. Journal of Translational Medicine. 2018;16(1). https://doi.org/10.1186/s12967-018-1532- PMID: 29879987 |
29879987 |
| 18 | 2017 | Chapter 2: Development and Validation of Disease Assays for Phenotypic Screening. Berg EL, Denker SP, O’Mahony A. In: Phenotypic Drug Discovery.; 2020:20-36. |
|
| 19 | 2017 | Mechanisms of Skin Toxicity Associated with Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators. Shah F, Stepan AF, O’Mahony A, Velichko S, Folias AE, Houle C, Shaffer CL, Marcek J, Whritenour J, Stanton R, Berg EL. Cell Chemical Biology. 2017;24(7):858–869.e5. https://doi.org/10.1016/j.chembiol.2017.06.003 . PMID: 28669525 |
28669525 |
| 20 | 2017 | Phenotypic Screening – Drug Discovery Today: Technologies. https://www.sciencedirect.com/journal/drug-discovery-today-technologies/vol/23/suppl/C. | |
| 21 | 2016 | Next-Generation Risk Assessment Case Study for Coumarin in Cosmetic Products. Baltazar MT, Cable S, Carmichael PL, Cubberley R, Cull T, Delagrange M, Dent MP, Hatherell S, Houghton J, Kukic P, Li H, Lee M-Y, Malcomber S, Middleton AM, Moxon TE, Nathanail AV, Nicol B, Pendlington R, Reynolds G, Reynolds J, White A, Westmoreland C. A Toxicol Sci. 2020;176(1):236-252. |
32275751 |
| 22 | 2016 | Btk inhibition treats TLR7/IFN driven murine lupus. Bender AT, Pereira A, Fu K, Samy E, Wu Y, Liu-Bujalski L, Caldwell R, Chen Y-Y, Tian H, Morandi F, Head J, Koehler U, Genest M, Okitsu SL, Xu D, Grenningloh R. Clinical Immunology. 2016;164:65-77. |
26821304 |
| 23 | 2016 | Identification of a chemical probe for family VIII bromodomains through optimization of a fragment hit. Gerstenberger BS, Trzupek JD, Tallant C, Fedorov O, Filippakopoulos P, Brennan PE, Fedele V, Martin S, Picaud S, Rogers C, Parikh M, Taylor A, Samas B, O’Mahony A, Berg E, Pallares G, Torrey AV, Treiber DK, Samardjiev IJ, Nasipak BT, Padilla-Benavides T, Wu Q, Imbalzano AN, Nickerson JA, Bunnage ME, Muller S, Knapp S, Owen DR. J Med Chem. 2016;59(10):4800-4811. https://doi.org/10.1021/acs.jmedchem.6b00012. |
27115555 |
| 24 | 2015 | Elucidating Mechanisms of Toxicity Using Phenotypic Data from Primary Human Cell Systems—A Chemical Biology Approach for Thrombosis-Related Side Effects. Berg EL, Polokoff MA, O’Mahony A, Nguyen D, Li X. International Journal of Molecular Sciences. 2015;16(1):1008-1029. https://doi.org/10.3390/ijms16011008. |
25569083 |
| 25 | 2015 | CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Hammitzsch A, Tallant C, Fedorov O, O’Mahony A, Brennan PE, Hay DA, Martinez FO, Al-Mossawi MH, de Wit J, Vecellio M, Wells C, Wordsworth P, Muller S, Knapp S, Bowness P. Proc Natl Acad Sci USA. 2015;112(34):10768-10773. https://doi.org/10.1073/pnas.1501956112. |
26261308 |
| 26 | 2015 | DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner. Gillard GO, Collette B, Anderson J, Chao J, Scannevin RH, Huss DJ, Fontenot JD. Journal of euroimmunology. 2015;283:74-85. https://doi.org/10.1016/j.jneuroim.2015.04.006 . |
26004161 |
| 27 | 2015 | Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694. Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A, Owens TD, Verner E, Brameld KA, Funk JO, Hill RJ, Johnson AJ, Dubovsky JA. J Biol Chem. 2015;290(10):5960-5978. https://doi.org/10.1074/jbc.M114.614891. |
25593320 |
| 28 | 2014 | Consideration of the cellular microenvironment: physiologically relevant co-culture systems in drug discovery. Berg EL, Hsu Y-C, Lee JA. Adv Drug Deliv Rev. 2014;69-70:190-204. https://doi.org/10.1016/j.addr.2014.01.013. |
24524933 |
| 29 | 2014 | Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Kleinstreuer NC, Yang J, Berg EL, Knudsen TB, Richard AM, Martin MT, Reif DM, Judson RS, Polokoff M, Dix DJ, Kavlock RJ, Houck KA. Nature Biotechnology. 2014;32(6):583–591. http://doi.org/10.1038/nbt.2914. |
24837663 |
| 30 | 2014 | Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies. Haselmayer P, Camps M, Muzerelle M, El Bawab S, Waltzinger C, Bruns L, Abla N, Polokoff MA, Jond-Necand C, Gaudet M, Benoit A, Bertschy Meier D, Martin C, Gretener D, Lombardi MS, Grenningloh R, Ladel C, Petersen JS, Gaillard P, Ji H. Front Immunol. 2014;5:233. https://doi.org/10.3389/fimmu.2014.00233 . |
24904582 |
| 31 | 2014 | Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Ciceri P, Muller S, O’Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, Treiber DK, Knapp S. Nature Chemical Biology. 2014;10(4):305-312. https://doi.org/10.1038/nchembio.1471. |
24584101 |
| 32 | 2013 | Regulation of IL-17A Production Is Distinct from IL-17F in a Primary Human Cell Co-culture Model of T Cell-Mediated B Cell Activation. Melton AC, Melrose J, Alajoki L, Privat S, Cho H, Brown N, Plavec AM, Nguyen D, Johnston ED, Yang J, Polokoff MA, Plavec I, Berg EL, O’Mahony A. PLOS ONE. 2013;8(3):e58966. https://doi.org/10.1371/journal.pone.0058966. |
23505568 |
| 33 | 2013 | Building Predictive Models for Mechanism-of-Action Classification from Phenotypic Assay Data Sets. Berg EL, Yang J, Polokoff MA. J Biomol Screen. 2013;18(10):1260-1269. https://doi.org/10.1177/1087057113505324. |
24088371 |
| 34 | 2012 | A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation. Bergamini G, Bell K, Shimamura S, Werner T, Cansfield A, Muller K, Perrin J, Rau C, Ellard K, Hopf C, Doce C, Leggate D, Mangano R, Mathieson T, O’Mahony A, Plavec I, Rharbaoui F, Reinhard F, Savitski MM, Ramsden N, Hirsch E, Drewes G, Rausch O, Bantscheff M, Neubauer G. Nature Chemical Biology. 2012;8(6):576-582. https://doi.org/10.1038/nchembio.957. |
22544264 |
| 35 | 2010 | A Novel Framework for Predicting In Vivo Toxicities from In Vitro Data Using Optimal Methods for Dense and Sparse Matrix Reordering and Logistic Regression. DiMaggio PA, Subramani A, Judson RS, Floudas CA. Toxicol Sci. 2010;118(1):251-265. https://doi.org/10.1093/toxsci/kfq233. |
20702588 |
| 36 | 2016 | Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin. Smith SH, Peredo CE, Takeda Y, Bui T, Neil J, Rickard D, Millerman E, Therrien J-P, Nicodeme E, Brusq J-M, Birault V, Viviani F, Hofland H, Jetten AM, Cote-Sierra J. PLOS ONE. 2016;11(2):e0147979. |
26870941 |
서비스 절차
서비스 문의